|
|
|
| Comparison of two drugs in the treatment of first-episode schizophrenia |
| PANG Junwei, ZHENG Gaojian, ZHANG Weihua, TANG Xu
|
| Department of Psychiatry, The Second People's Hospital of Taizhou, Taizhou, Zhejiang 317200, China |
|
|
|
|
Abstract Objective To compare the effectiveness of blonanserin and olanzapine in the treatment of first-episode schizophrenia, so as to provide the basis for the medication choice for the treatment of first-episode schizophrenia. Methods A total of 98 patients with first-episode schizophrenia admitted to the Second People's Hospital of Taizhou City were selected and randomly divided into the olanzapine group and the blonanserin group for a treatment period of two months. The Positive and Negative Syndrome Scale (PANSS), Pittsburgh Sleep Quality Index (PSQI), MATRICS Consensus Cognitive Battery (MCCB) were used to investigate the improvement of symptoms, sleep quality and cognitive function before and after treatment, respectively, and the level of prolactin was detected. The generalized estimation equation was used to compare the differences between the two groups. The adverse reactions of the two groups were recorded and the safety of medication was evaluated. Results Forty-nine patients each group were included, with 29 males and a mean age of (37.22±7.17) years in the olanzapine group, and 27 males and a mean age of (37.54±7.31) years in the blonanserin group. There were no significant differences in gender, age, disease course and educational duration between the two groups (all P>0.05). The scores of positive symptom, negative symptom, general psychopathology and overall PANSS in the two groups after treatment were decreased compared with those before (all P<0.05). However, there was no significant difference between the two groups, and no interaction between the drugs and treatment duration (all P>0.05). The MCCB score of the blonanserin group was higher than that of the olanzapine group, while the PSQI score and the prolactin level of the blonanserin group were lower than that of the olanzapine group, and there was an interaction between the drugs and treatment duration (all P<0.05). The incidence of adverse reactions in the blonanserin group was 6.12%, which was lower than that in the olanzapine group of 20.41% (P<0.05). Conclusion Either blonanserin or olanzapine can improve psychotic symptoms inpatients with first-episode schizophrenia, while blonanserin is more effective than olanzapine in improving sleep quality, cognitive function and reducing prolactin level, and has higher safety.
|
|
Received: 16 November 2023
Revised: 06 March 2024
Published: 17 May 2024
|
|
|
|
|
|
[1] 陈剑英,程文桃,林瑞钱,等.第一代与第二代抗精神病药物对慢性精神分裂症患者代谢综合征的影响[J].海峡药学,2021,33(9):132-134.
[2] 侯钦强,郎小娥,梁瑛,等.首发精神分裂症病人言语性幻听与血清泌乳素水平的相关性分析[J].中西医结合心脑血管病杂志,2022,20(12):2285-2289.
[3] 聂莲莲,潘胜琼,吴龙辉.居家精神分裂症患者服药依从性影响因素分析[J].预防医学,2019,31(12):1283-1286.
[4] KISHI T,MATSUI Y,MATSUDA Y,et al.Efficacy,tolerability,and safety of blonanserin in shizophrenia:an updated and extended systematic review and meta-analysis of randomized controlled trials[J].Pharmacopsychiatry,2019,52(2):52-62.
[5] HARVEY P D,NAKAMURA H,MURASAKI M.Blonanserin versus haloperidol in Japanese patients with schizophrenia:a phase 3,8-week,double-blind,multicenter,randomized controlled study[J].Neuropsychopharmacol Rep,2019,39(3):173-182.
[6] 陆林.沈渔邨精神病学(第6版)[M].北京:人民卫生出版社,2018:382.
[7] 司天梅,杨建中,舒良,等.阳性和阴性症状量表(PANSS,中文版)的信、效度研究[J].中国心理卫生杂志,2004,18(1):45-47.
[8] BUYSSE D J,REYNOLDS C F,MONK T H,et al.The Pittsburgh Sleep Quality Index:a new instrument for psychiatric practice and research[J].Psychiatry Res,1989,28(2):193-213.
[9] SHI C,KANG L,YAO S Q,et al.The MATRICS Consensus Cognitive Battery (MCCB):co-norming and standardization in China[J].Schizophr Res,2015,169(1/2/3):109-115.
[10] LI Y D,GE J,LUO Y J,et al.High cortical delta power correlates with aggravated allodynia by activating anterior cingulate cortex GABAergic neurons in neuropathic pain mice[J].Pain,2020,161(2):288-299.
[11] SCHWARTZ J C,DIAZ J,PILON C,et al.Possible implications of the dopamine D(3)receptor in schizophrenia and in antipsychotic drug actions[J].Brain Res Brain Res Rev,2000,31(2/3):277-287.
[12] KOH K,HAMADA A,HAMADA Y,et al.Possible involvement of activated locus coeruleus-noradrenergic neurons in pain-related sleep disorders[J].Neurosci Lett,2015,589:200-206.
[13] OHOYAMA K,YAMAMURA S,HAMAGUCHI T,et al.Effect of novel atypical antipsychotic,blonanserin,on extracellular neurotransmitter level in rat prefrontal cortex[J].Eur J Pharmacol,2011,653(1/2/3):47-57.
[14] DEEKS E D,KEATING G M.Blonanserin:a review of its use in the management of schizophrenia[J].CNS Drugs,2010,24(1):65-84.
[15] 孙磊,罗国帅,陈清刚.布南色林与利培酮对首发精神分裂症患者认知功能、泌乳素和血脂的影响研究[J].中国慢性病预防与控制,2022,30(3):214-217.
[16] HOWES O D,SHATALINA E.Integrating the neurodevelopmental and dopamine hypotheses of schizophrenia and the role of cortical excitation-inhibition balance[J].Biol Psychiatry,2022,92(6):501-513.
[17] 于欣,司天梅,陆峥,等.布南色林治疗精神分裂症的临床应用中日专家建议[J].中国心理卫生杂志,2021,35(9):751-757. |
|
|
|
